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Risperidone-induced weight gain and reduced locomotor activity in juvenile 
female rats: the role of histaminergic and NPY pathways 
Abstract 
Second generation antipsychotic drugs (SGAs) such as risperidone are increasingly prescribed (mostly 
for off-label use) to children and adolescents for treating various mental disorders. SGAs cause serious 
weight gain/obesity and other metabolic side-effects. This study aimed to establish an animal model of 
risperidone-induced weight gain in female juvenile rats, and to investigate the effects of risperidone on 
the expression of hypothalamic histaminergic H1 receptors (H1R) and neuropeptides, and their 
association with weight gain. Female Sprague Dawley rats were treated orally with risperidone (0.3 mg/kg, 
3 times/day) or vehicle (control) starting from postnatal day (PD) 23 (±1 day) for 3 weeks (a period 
corresponding to the childhood-adolescent period in humans). In the female juvenile rats, risperidone 
treatment increased food intake and body weight gain, which started to appear after 12 days' treatment. 
Risperidone also significantly decreased the locomotor activity of the female rats. Consistently, 
risperidone significantly elevated mRNA expression of hypothalamic H1R, neuropeptide Y (NPY), and 
agouti-related peptide (AgRP) compared to controls, and H1R and NPY levels were correlated with 
risperidone enhanced weight gain and food intake in the female juvenile rats. However, risperidone did not 
affect hypothalamic proopiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript 
(CART) mRNA expression. Therefore, these results suggested that risperidone elevated appetite and body 
weight gain in juveniles via regulation of the hypothalamic H1R, NPY and AgRP pathways, as well as by 
reducing activity. 
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Second Generation Antipsychotic drugs (SGAs) such as risperidone are increasingly 
prescribed (mostly for off-label use) to children and adolescents for treating various mental 
disorders. SGAs cause serious weight gain/obesity and other metabolic side-effects. This 
study aimed to establish an animal model of risperidone-induced weight gain in female 
juvenile rats, and to investigate the effects of risperidone on the expression of hypothalamic 
histaminergic H1 receptors (H1R) and neuropeptides, and their association with weight gain. 
Female Sprague Dawley rats were treated orally with risperidone (0.3 mg/kg, 3 times/day) or 
vehicle (control) starting from postnatal day (PD) 23 (±1 day) for 3 weeks (a period 
corresponding to the childhood-adolescent period in humans). In the female juvenile rats, 
risperidone treatment increased food intake and body weight gain, which started to appear 
after 12 days’ treatment. Risperidone also significantly decreased the locomotor activity of 
the female rats. Consistently, risperidone significantly elevated mRNA expression of 
hypothalamic H1R, neuropeptide Y (NPY), and agouti-related peptide (AgRP) compared to 
controls, and H1R and NPY levels were correlated with risperidone enhanced weight gain and 
food intake in the female juvenile rats. However, risperidone did not affect hypothalamic 
proopiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART) 
mRNA expression. Therefore, these results suggested that risperidone elevated appetite and 
body weight gain in juveniles via regulation of the hypothalamic H1R, NPY and AgRP 
pathways, as well as by reducing activity. 
 






LIST OF ABBREVIATIONS 
5-HT2AR, serotonergic 5-HT2A receptor 
5-HT2CR, serotonergic 5-HT2C receptor 
AgRP, agouti-related peptide  
Arc, arcuate nuclei  
CART, cocaine- and amphetamine-regulated transcript 
D2R, dopaminergic D2 receptor 
H1R, histaminergic H1 receptor  
NPY, neuropeptide Y 
PD, postnatal day  
POMC, proopiomelanocortin  
qRT-PCR, quantitative real-time polymerase chain reaction  
SGAs, second generation antipsychotics 




Over recent decades, antipsychotic prescriptions have sharply increased, not only to treat 
childhood-onset schizophrenia, but have also been widely used in children and adolescents to 
treat mental disorders such as bipolar disorder, autism and attention deficit hyperactivity 
disorder [1-4]. The majority of antipsychotic drugs prescribed in children and adolescents are 
second generation antipsychotics (SGAs) including risperidone and olanzapine, which have 
serious weight gain and other metabolic side-effects [5-10]. Of even greater concern, 
however, is evidence clearly demonstrating that the paediatric population appears to be at 
greater risk than adults for SGA-induced weight gain and metabolic side-effects [11]. 
 
Risperidone is the most commonly prescribed antipsychotic drug in paediatric patients [4, 12, 
13]. It has been repeatedly reported that risperidone is associated with much higher weight 
gain in children and adolescents than those in adults [14-17]. For example, a meta-analysis of 
placebo controlled trials over 3000 paediatric and adult subjects using risperidone found that 
it can cause over three times more body weight gain (by percentage of weight changes) in 
youths than in adults [18].  A clinical trial also confirmed that after an average of 2.9 years’ 
of risperidone treatment, 99 children and adolescent patients suffered a significant weight 
gain and increased body mass index (BMI) [19].    
 
In contrast to first generation antipsychotics (such as haloperidol) that are largely potent and 
selective dopamine D2 receptor (D2R) antagonists, SGAs have binding affinities for various 
neurotransmitter receptors, such as D2R, serotonin 5-HT2A (5-HT2AR) and 5-HT2C receptors 
(5-HT2CR) and histamine H1 receptors (H1R) [20]. Accumulated evidence from our 
laboratory and other laboratories has revealed that dopamine D2R and 5-HT2AR play a critical 
role in the therapeutic effects of SGAs including risperidone, while 5-HT2CR and H1R 
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contribute to weight gain/obesity side-effects [21-24]. In particular, using an adult rat model 
for olanzapine-induced weight gain, we previously identified that hypothalamic H1R is a key 
factor for the olanzapine-induced weight gain side-effect [25, 26]. Since risperidone is also a 
potent antagonist for H1R [20], H1R may also play a key role in risperidone-induced weight 
gain.  
 
Using the adult female rat model for antipsychotic-induced weight gain, it has been 
repeatedly revealed that olanzapine elevated the expression of appetite stimulating 
neuropeptides in the hypothalamus, including neuropeptide Y (NPY) and agouti-related 
peptide (AgRP), while decreasing appetite inhibiting neuropeptides such as 
proopiomelanocortin (POMC) [25, 27-29]. On the other hand, H1R is independent of POMC 
regulation [30], but links to NPY expression [31]. Evidence has also shown that increased 
activities of NPY and AgRP expression by olanzapine were through blocking the H1R [25, 26, 
32]. There have been two previous studies investigating the effects of risperidone on 
expression of hypothalamic neuropeptides in male rats, however the results were 
contradictory and puzzling [33, 34]. Ota and his colleagues found that 3-week treatment of 
risperidone in adult male rats did not have any effect on the expression of hypothalamic NPY, 
AgRP, POMC and CART, even though treatment increased food intake [33, 35]. The other 
study reported some puzzling results in four-week old male rats; although food intake 
increase and weight gain were observed, four weeks’ treatment of risperidone significantly 
decreased both appetite stimulating neuropeptides (NPY and AgRP) and appetite inhibiting 
neuropeptide POMC, while the other appetite inhibiting neuropeptide CART mRNA 
expression was increased [34]. Gothelf and colleagues revealed that after 4 weeks’ of 
antipsychotic administration to male adolescent schizophrenic inpatients, BMI was 
significantly enhanced in those treated with olanzapine, but not in those treated with 
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haloperidol, which was associated with an increase in caloric intake [36]. Another study 
found that first-attack psychotic patients had reduced plasma levels of NPY and α-
melanocyte melanocytestimulating hormone (α-MSH), but an increased plasma CART level 
compared to the control; four weeks’ risperidone treatment did not change circulating NPY, 
α-MSH, and CART  levels  [8]. A recent review paper demonstrated that the effect of SGAs 
including risperidone is associated with food intake, physical activity and energy expenditure 
in both children and adult patients [37].  
 
To date, there has been no study investigating the hypothalamic regulatory mechanisms 
underlying risperidone-induced weight gain in female juvenile rats. Therefore, in this study, 
we investigated the effects of risperidone on body weight and food intake in female juvenile 
rats and further investigated its effects on expression of hypothalamic H1R, NPY, POMC, 
AgRP and CART mRNA expression, and their relationships with changes in body weight 
gain and food intake. Since our recent studies in adult rat models have demonstrated that 
olanzapine-induced weight gain is associated with a significant decrease in locomotor activity 
[38-40], and decreased activity was also observed after acute administration of antipsychotics 
during early development [41], the locomotor activity of female juvenile rats was also 
examined in this study. 
 
2. Materials and Methods  
2.1 Animals Housing, Administration and Drug Treatment 
Timed pregnant Sprague Dawley rats (at gestation day 16) were obtained from the Animal 
Resources Centre (Perth, WA, Australia). They were housed in individual cages and allowed 
ad-libitum access to standard laboratory chow diet (3.9 kcal/g: 10% fat, 74% carbohydrate, 
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16% protein) and water under a light (07:00 to 19:00) and dark (19:00 to 7:00) cycle and 
temperature control (22ºC) throughout the experiment [32, 38]. Day of birth was recognised 
as postnatal day (PD) 0. Pups were sexed on PD14, and 24 female rats were weaned on PD21 
and housed in individual cages.  
 
Before the treatment procedures, rats were trained for self-administration of the drug by 
feeding them using 0.3 g cookie dough (including 30.9 % cornstarch, 30.9% sucrose, 6.3% 
gelatine, 15.5% casein, 6.4% fibre, 8.4% minerals and 1.6% vitamins) without drug twice a 
day during PD18-21. The postnatal female rats (PD23±1) were then randomly assigned to 
one of two treatment groups as follows: (1) risperidone (0.3 mg/kg, t.i.d., Janssen, USA; 
n=12) or (2) vehicle (control; n=11) for 3 weeks (a period corresponding to the childhood-
adolescent period in humans) [42]. Drugs were prepared in advance by mixing with cookie 
dough pellets and droplets of water, and were administered 3 times per day (8±1 hours, 
interval) orally for 3 weeks [32, 38]. The rats in the control group received an equivalent 
pellet without drug. Rats were observed throughout the experiment to ensure all cookie dough 
pellets were consumed. Body weight, food intake and water intake were measured and 
recorded once every two days. This study was approved by the Animal Ethics Committee, 
University of Wollongong, Australia (AE12/20); and all the procedures complied with the 
Australian Code of Practice for the Care and Use of Animals for Scientific Purposes (2004).  
 
After completing treatment, all rats were sacrificed (without fasting) by carbon dioxide 
asphyxiation. Brain samples were collected and stored in a -80 ºC freezer until analysis. The 
hypothalamic nuclei were dissected based on the rat brain atlas [43]. In brief, rat brains were 
cut at −10.5 °C ± 1.5 °C into 500µm coronal sections. The nuclei were dissected using micro-
punches (57401, Stoelting Co, USA), targeted at the arcuate nuclei (Arc). Since the Arc is 
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small, the punched tissue primarily contained Arc, but included adjacent ventromedial 
nucleus (VMH), therefore the punched tissue was labelled as the mediobasal hypothalamus. 
The dissected tissue was placed into 1.5 ml Eppendorf tubes, and stored at −80 °C until use 
for qRT-PCR [25]. 
 
2.2 Open Field Test 
An open field test was performed on PD36 ± 1 day in order to determine whether risperidone 
could affect the locomotor activity of rats. A rat was placed in the centre of a black 
rectangular arena (60 × 60 cm2, 40 cm high) that was exposed to lighting of 25 lux across the 
entire arena. A video camera was used to record the behaviour of the rats for 30 minutes from 
the central top of the arena. The locomotor activity of the rats was analysed using EthoVision 
Color-Pro software (Noldus Information Technology, Wageningen, The Netherlands) [38] 
and the distance moved (cm) and velocity (cm/s) were measured.  
 
2.3 Quantitative real-time PCR  
Quantitative real-time polymerase chain reaction (qRT-PCR) was applied to detect mRNA 
expression of H1R, NPY, POMC, AgRP and CART in the mediobasal hypothalamus. Total 
RNA was isolated using a PureLinkTM RNA extraction kit (Invitrogen Life Technologies, 
Carlsbad, CA, USA). RNA quality was then assessed by Nanodrop (ThermoFisher Scientific, 
MA, USA). Aliquots of total RNA were digested within a spin column RNase-free DNase I 
kit (MO BIO Laboratories, Inc., CA, USA) to remove residual genomic DNA. The digested 
RNA was purified by ethanol precipitation, dried and dissolved in RNA Storage Solution 
(Ambion, Inc., Austin, TX). Aliquots of RNA were subjected to reverse transcription using 
super-script II RNase H-Reverse Transcriptase. To ensure the total RNA was free from 
genomic DNA after DNase digestion, aliquots of total RNA were subjected to PCR using a 
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pair RT-control. First-strand cDNA was synthesised from RNA with Superscript® VILOTM 
cDNA synthesis kit (Life Technologies, NSW, Australia) with 20 µL reaction volume 
containing 9 µL cDNA, 10 µL SYBR Green PCR Master Mix (Applied Biosystems, Boston, 
MA), 1 µL each of primers. 
 
Real-time quantitative PCR was performed in triplicate using TaqMan® Gene Expression 
Assays (Applied Biosystems, Foster City, USA) in combination with continuous SYBR 
Green detection (Applied Biosystems) on LightCycler®480 (Roche, Penzberg, Germany). 
The assay (Life Technologies, NSW, Australia) identifications of the target genes were H1 
receptor (Rn00566691 s1); NPY (Rn01410145 m1); POMC (Rn00595020 m1); AgRP 
(Rn01431703 g1), and CART (Rn01645174 m1). β-actin (Rn00667869 m1) and GAPDH 
(Rn01775763 g1) were expressed as endogenous controls. The RT-PCR plates were run by 
polymerase amplification for 10 mins at 95 ºC, followed by 40 cycles of denaturation at 95 ºC 
for 15s, and annealing and extending at 60 ºC for 1 min. The 2−∆∆T method was used to 
calculate the results [44]. 
 
2.4 Statistical Analysis 
Statistical analysis was performed using SPSS (IBM version 19.0, SPSS Inc., NY, USA). The 
Kolmogorov-Smirnov test was used to examine the distribution of data from all experiments. 
Weight gain, food intake and water intake data were analysed by two-way repeated ANOVAs 
(Treatment × Days as repeated measures). Behavior and mRNA expression were analyzed by 
independent-samples T test to compare the risperidone and control groups. Pearson’s 
correlation test was used to analyse the relationships among the measurements. All data were 





3.1 Effects of risperidone on body weight gain, food intake and water intake  
Risperidone had no effects on weight gain in the first 12 days of drug treatment (Figure 1A), 
however it was shown that body weight gain was significantly greater in the risperidone 
group compared to the controls from day 14 (Figure 1A). Two-way repeated ANOVAs 
(Treatment × Days as repeated measures) showed significant main effects of Days 
(F3,63=193.915, p<0.001), Treatment (F1,21=8.939, p<0.01), and significant interaction 
between the two factors (F3,63=5.484, p<0.01) on accumulated body weight gain. Risperidone 
significantly increased the accumulated body weight gain on treatment day 14 (t=-2.535, 
df=21, p=0.019), day 16 (t=-2.712, df=21, p=0.013), day 18 (t=-3.345, df=21, p=0.003) and 
day 20 (t=-2.534, df=21, p=0.018) (Figure 1A). There was no significant difference between 
risperidone and control groups in leg length (Risperidone, 4.55±0.04 cm vs. Control, 
4.43±0.06 cm; t=-1.562, df=21, p=0.133). 
 
Consistent with the weight gain data, there was no difference in food intake on the first 12 
days’ of drug treatment, while risperidone-treated juvenile rats showed significant enhanced 
accumulated food intake compared with controls during treatment days 14-20 (Figure 1B). 
There were significant main effects of Treatment (F1,21=6.222, p<0.05) and Days 
(F3,63=865.998, p<0.001), and significant interaction between the two factors (F3,63=3.895, 
p<0.05) (Figure 1B). Risperidone-treated juvenile rats also had higher average feeding 
efficiency (accumulated body weight gain/accumulated food intake during treatment days 14-
20) than the control (t=-2.707, df=21, p=0.013) (Figure 1C). Moreover, there were highly 
positive correlations between total body weight gain and total food intake (r=0.581, p<0.01), 




There was also no change of water intake in the first 12 days’ of treatment. From treatment 
day 14 (Figure 1D), the two-way repeated ANOVAs (Treatment × Days as repeated measures) 
also showed the significant main effects of Treatment (F1,21=5.503, p<0.05) and Days 
(F3,63=642.025, p<0.001), but there was no significant interaction between the two factors 
(F3,63=0.738, p=0.533). There was a significant difference of water intake between 
risperidone treatment and control on treatment day 14 (t=-2.376, df=21, p=0.027), day 16 (t=-
2.457, df=21, p=0.023), day 18 (t=-2.451, df=21, p=0.023), and day 20 (t=-2.447, df=21, 
p=0.023) (Figure 1D). 
 
3.2 Effects of risperidone treatment on locomotor activity  
Figure 2A shows examples of locomotor activity of rats treated with risperidone and vehicle 
(controls). Compared to the control, the rats treated with risperidone had significantly 
decreased total distance moved (t=2.951, df=21, p<0.01) and total lower velocity (t=3.310, 
df=21, p<0.01) (Figures 2B and C). Furthermore, it is important to note that total distance 
moved was negatively correlated with total body weight gain (r=-0.569, p<0.01), and feeding 
efficiency (r=-0.444, p<0.05). The velocity also negatively correlated with total body weight 
gain (r=-0.610, p<0.01), and feeding efficiency (r=-0.474, p<0.05). 
  
3.3 Effects of risperidone treatment on expression of hypothalamic H1R, NPY, POMC, 
AgRP and CART 
Figure 3 presents the effects of risperidone treatment on the mRNA expression of 
hypothalamic H1R, NPY, POMC, AgRP and CART in female juvenile rats compared with 
the control. Risperidone treatment significantly upregulated mRNA expression of H1R (+23%, 
t=-3.784, df=9, p=0.004) and AgRP (+155%, t=-2.917, df=9, p=0.021), and a tendency to 
elevate NPY (t=-2.124, df=9, p=0.055), compared with the control (Figure 3). Hypothalamic 
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H1R mRNA expression was positively correlated to NPY (r=0.579, p<0.05) and AgRP 
(r=0.565, p<0.05) levels. There were positive correlations between hypothalamic NPY 
expression and body weight gain (r=0.678, p<0.05), and feeding efficiency (r=0.560, p<0.05).  
 
4. Discussion  
This study revealed the effects of risperidone treatment on body weight, food and water 
intake, locomotor activity, and mRNA expression of H1R and hypothalamic neuropeptides 
POMC, NPY, AgRP and CART in juvenile (PD23-44) female rats. To our knowledge, this is 
the first study into the effects of risperidone on hypothalamic appetite signalling in a young 
female rat model of risperidone-induced weight gain. Our results showed that risperidone 
treatment at 0.3 mg/kg, t.i.d. (equivalent to the recommended dosage in the clinic) 
significantly increased body weight gain in female juvenile rats. We found that risperidone-
induced weight gain and food intake was associated with increased histamine H1R and NPY 
levels in the hypothalamus. Furthermore, our results showed that risperidone-induced weight 
gain is associated with a significant decrease in locomotor activity in juvenile female rats. 
Our findings coincide with previous reports on children/adolescents [17, 45-48]. 
 
4.1 Choice of female rats  
Female rats were chosen in this study, both because risperidone-induced weight gain has 
been reported in a previous study using female juvenile rats [49] and also because, while 
SGA-induced weight gain has been consistently established in females using various SGAs 
including risperidone and olanzapine [27, 32, 38, 40, 50-53], it could not be consistently 
modelled in male rodents. While risperidone-induced weight gain has been well modelled in 
female rodents [49, 52-54], it has been established in male rats in some studies [34] but not 




4.2 Late onset of weight gain 
The increase in weight gain and food intake caused by risperidone treatment in this study 
occurred after 12 days’ treatment. This was unexpected, since previous studies in adult 
models often showed that risperidone and olanzapine increased food intake and weight gain 
after 3-4 days’ treatment [38, 52, 54, 56]. Risperidone was also reported to increase food 
intake and body weight after 3 days’ treatment in female rats at 7-weeks old [49]. In this 
study, however, much younger female animals (23-days old) were used. These results 
suggest a possible age difference in the onset of increased weight gain and food intake 
caused by risperidone treatment, although we could not fully explain it at this stage. Further 
study is needed to address this issue. 
 
4.3 Dosage 
According to dosage translation between humans and rats based on body surface following 
the FDA guideline for clinical trials [57, 58], the risperidone dosage in this study (0.3 mg/kg) 
is equivalent to the human dosage (1.8 mg in human children at 25 kg body weight, or 2.8 
mg in human children at 40 kg body weight). The half-life of active moiety (including 
risperidone and 9-hydroxyrisperidone) is 8.6 hours in the rat brain and 11.4 hours in rat 
plasma after an oral dose risperidone [59], compared to an average 20 hours in human 
plasma (up to 30 hours in poor metabolisers) [60]. This drug was therefore delivered orally 3 
times/day (at 8 hour intervals) in this study to ensure a consistently high concentration that 
better mirrors the human scenario of oral administration [38]. The risperidone (0.3 mg/kg, 
t.i.d.) used in this study is therefore within the range of recommended dosage used in 
paediatric patients (0.5-3 mg/day) [1, 4, 60], and does not reach the maximum indicated 
paediatric dosage (6 mg/day) [61]. At this dosage, the risperidone drug treatment reaches 
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between 65-90% dopamine D2 receptor occupancy [62, 63]. Risperidone treatment at 0.5 
mg/kg (once daily, intraperitoneal or subcutaneous injection) has been reported to 
significantly increase weight gain and food intake in female adult/7-week old rats [49, 52, 54] 
and in female adult mice risperidone (2 mg/kg, orally twice per day) for 3 weeks led to 
significantly increased body weight gain and food intake compared to controls [53]. 
 
4.4 Hypothalamic H1R mRNA expression 
Histamine H1R is highly expressed in the hypothalamic Arc and VMH, which play significant 
roles in body weight regulation, food intake and energy expenditure [64, 65]. Two meta-
analyses of clinical data have found that the H1R antagonistic property of antipsychotics is 
strongly correlated with their body weight gain side-effect [66, 67]. Studies in animal models 
have further evidenced that hypothalamic H1R is a major contributor for 
olanzapine/clozapine-induced weight gain and obesity [25, 26, 32, 68, 69]. Risperidone has 
high binding affinity with H1R [20], and our examination of mRNA expression of 
hypothalamic H1R found a significant increase in hypothalamic H1R mRNA expression in the 
risperidone treatment group. This result is consistent with previous findings that olanzapine 
(a potent H1R antagonist) increased hypothalamic H1R mRNA expression associated with 
olanzapine-induced weight gain [25, 26].    
 
4.5 mRNA expressions of hypothalamic neuropeptides 
In this study, we revealed that hypothalamic NPY and AgRP mRNA expression were 
elevated by risperidone treatment in young female rats, which were correlated with 
risperidone-induced food intake and weight gain. This is also consistent with previous reports 
in female rat models for olanzapine-induced weight gain with a significant increase of NPY 
mRNA expression [25, 27-29, 70]. In addition, it has previously been found that acute ICV 
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olanzapine treatment led to an upregulated AgRP level in male adult rats [17]. Furthermore, 
our recent study showed an elevated AgRP mRNA expression after two weeks’ treatment 
with olanzapine in female adult rats [25]. Corresponding with our findings, Gruber and 
colleagues reported that NPY-like immunoreactivity was increased in the hypothalamic 
region but decreased in the ventral striatum of male Wistar rats (weighing 130 g at the 
beginning of the experiment) after 4-weeks’ risperidone treatment [71]. However, results 
contradictory to this study were reported in one recent study, where 4 weeks’ treatment of 
risperidone in 4-week old male rats caused a decrease in hypothalamic NPY/AgRP 
expression; instead, there was a significant decrease in hypothalamic POMC mRNA 
expression induced by risperidone treatment, while CART mRNA expression increased  [34]. 
In view of the fact that hypothalamic NPY and AgRP are appetite stimulating neuropeptides, 
and POMC and CART are appetite inhibiting neuropeptides, these results are puzzling and 
hard to explain, because a significant increase in weight gain and food intake was observed in 
these risperidone treated male rats [34]. In this study, we did not find any changes in POMC 
and CART mRNA expression after risperidone treatment in female juvenile rats. This was 
different from previous findings in the olanzapine-induced weight gain model,  in which 
olanzapine treatment was found to decrease POMC mRNA expression in adult female rats 
[25, 27-29, 70]. However, although first-attack psychotic patients had higher plasma NPY 
and α-MSH, but lower CART levels than the control, four weeks’ risperidone treatment did 
not change NPY, α-MSH, and CART levels  [8]. Therefore, further studies are necessary to 
investigate the mechanisms underlying risperidone-induced weight gain, particularly in 
juveniles.  
 
4.6 Reduced locomotor activity 
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It is worth noting that weight gain induced by antipsychotics is not only attributed to 
increased energy intake; reduced energy expenditure may also play an important role as 
proven in olanzapine-induced weight gain rat models [38, 39, 56, 72]. In fact, this study 
found that risperidone reduced locomotor activity in juvenile female rats, which is consistent 
with a number of studies in which risperidone was proven to reduce locomotor activity in 
rats and mice [53, 73, 74]. Clinical studies have also reported that risperidone treatment 
reduced hyperactivity in children with attention-deficit and bipolar disorder [37, 75, 76]. 
Therefore, the decreased activity exhibited in the present study may also play a role in 
risperidone-induced body weight gain. Furthermore, this study found that risperidone 
treatment also increased water intake, which might reflect the dry mouth side-effects 
following risperidone treatment often observed in clinics [77]. 
 
5. Conclusion 
Overall, this study has shown that oral risperidone treatment induced significantly increased 
weight gain and food intake in juvenile female rats. Risperidone-induced body weight gain 
and hyperphagia could be through regulating histamine H1R, NPY and AgRP signalling in 
the hypothalamus, as well as reducing locomotor activity. Since weight gain and other 
metabolic abnormalities during childhood could strongly predict adult obesity and metabolic 
syndromes, paediatric subjects treated with antipsychotics such as risperidone face a much 
greater risk of obesity and other metabolic disorders in adulthood, which pose a major risk of 
premature cardiovascular morbidity and mortality in adults [78]. Therefore, further studies 
using the animal model are important for developing strategies to ameliorate risperidone-
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